Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 11/2019

01-11-2019 | Insulins | Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Has Technology Improved Diabetes Management in Relation to Age, Gender, and Ethnicity?

Authors: Leslie Eiland, Thiyagarajan Thangavelu, Andjela Drincic

Published in: Current Diabetes Reports | Issue 11/2019

Login to get access

Abstract

Purpose of Review

To review the current state of diabetes technology adoption and describe impact on outcomes in the context of age, gender, and ethnicity. We will discuss barriers and propose solutions that may help facilitate the adoption.

Recent Findings

We are witnessing rapid evolution and increase in adoption of diabetes technology in all its forms, including insulin delivery and glucose monitoring devices, mobile medical applications, and telemedicine. This technology has a great potential to improve diabetes-related outcomes, including acute and chronic complications as well as quality of life for people living with diabetes. However, currently available outcome data are showing modest efficacy and evidence for disparities when it comes to age, gender, and ethnicity.

Summary

Despite multiple barriers, the adoption of technology is steadily increasing. It is clear that disparities exist in terms of access to and use of technology, but they may be at least in part driven by unmet needs of end users and as such are not unsurmountable. While more research is needed to identify the specific causes for the disparities, future development of diabetes technology that is based on adaptation of behavioral theories has a potential to address the gaps. The disparities can be lessened by understanding the needs of end users and with improvement in personalization of technology, allowing the right device to be used by the right patient. Targeted interventions to increase awareness and education and help navigate the processes involved in currently available technology may help diminish the gaps in health equity.
Literature
1.
Anonymous Telehealth Basics. https://​www.​americantelemed.​org/​resource/​why-telemedicine/​.​ Accessed July 10 2019.
2.
American Diabetes Association. Diabetes technology: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S71–80.
3.
Lin MH, Connor CG, Ruedy KJ, Beck RW, Kollman C, Buckingham B, et al. Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. Diabetes Technol Ther. 2013;15:929–34.PubMedPubMedCentral
4.
5.
Tanenbaum ML, Hanes SJ, Miller KM, Naranjo D, Bensen R, Hood KK. Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabetes Care. 2017;40:181–7.PubMed
6.
•• Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther. 2019;21:66–72. This paper provides updated data from T1D Exchange, illustrating the impressive increase in adoption of technology over the last several years, but notably it does not correlate with improved glycemic control. PubMedPubMedCentral
7.
Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016;39:1378–83.
8.
9.
Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Coney J, et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care. 2007;30:1995–7.PubMed
10.
Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study. Diabetes Care. 2011;34:968–74.PubMedPubMedCentral
11.
Weisman A, Rovinski R, Farooqi MA, Lovblom LE, Halpern EM, Boulet G, et al. Commonly measured clinical variables are not associated with burden of complications in long-standing type 1 diabetes: results from the Canadian study of longevity in diabetes. Diabetes Care. 2016;39:e67–8.PubMed
12.
Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin N Am. 2010;39:641–54.
13.
American Diabetes Association. Older adults: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S139–47.
14.
15.
Matejko B, Cyganek K, Katra B, Galicka-Latala D, Grzanka M, Malecki MT, et al. Insulin pump therapy is equally effective and safe in elderly and young type 1 diabetes patients. Rev Diabet Stud. 2011;8:254–8.PubMedPubMedCentral
16.
• Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C, DIAMOND Study Group. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11:1138–46. This study demonstrates the benefits of CGM for people with T1DM and T2DM on multiple daily injections. PubMedPubMedCentral
17.
Briganti EM, Summers JC, Fitzgerald ZA, Lambers LNJ, Cohen ND. Continuous subcutaneous insulin infusion can be used effectively and safely in older patients with type 1 diabetes: long-term follow-up. Diabetes Technol Ther. 2018;20:783–6.PubMed
18.
Argento NB, Nakamura K. Personal real-time continuous glucose monitoring in patients 65 years and older. Endocr Pract. 2014;20:1297–302.PubMed
19.
Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012;35:32–8.PubMed
20.
LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104:1520–74.PubMedPubMedCentral
21.
Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8:863–73.PubMedPubMedCentral
22.
O'Connor MR, Carlin K, Coker T, Zierler B, Pihoker C. Disparities in insulin pump therapy persist in youth with type 1 diabetes despite rising overall pump use rates. J Pediatr Nurs. 2019;44:16–21.PubMed
23.
Sheikh K, Bartz SK, Lyons SK, DeSalvo DJ. Diabetes device use and glycemic control among youth with type 1 diabetes: a single-center, cross-sectional study. J Diabetes Res. 2018;2018:5162162.PubMedPubMedCentral
24.
Valenzuela JM, La Greca AM, Hsin O, Taylor C, Delamater AM. Prescribed regimen intensity in diverse youth with type 1 diabetes: role of family and provider perceptions. Pediatr Diabetes. 2011;12:696–703.PubMed
25.
Commissariat PV, Boyle CT, Miller KM, Mantravadi MG, DeSalvo DJ, Tamborlane WV, et al. Insulin pump use in young children with type 1 diabetes: sociodemographic factors and parent-reported barriers. Diabetes Technol Ther. 2017;19:363–9.PubMedPubMedCentral
26.
Wheeler BJ, Braund R, Galland B, Mikuscheva A, Wiltshire E, Jefferies C, et al. District health board of residence, ethnicity and socioeconomic status all impact publicly funded insulin pump uptake in New Zealand patients with type 1 diabetes. N Z Med J. 2019;132:78–89.PubMed
27.
Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390:2347–59.PubMedPubMedCentral
28.
Voormolen DN, DeVries JH, Sanson RME, Heringa MP, de Valk HW, Kok M, et al. Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): a multicentre randomized controlled trial. Diabetes Obes Metab. 2018;20:1894–902.PubMed
29.
Rys PM, Ludwig-Slomczynska AH, Cyganek K, Malecki MT. Continuous subcutaneous insulin infusion vs multiple daily injections in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials and observational studies. Eur J Endocrinol. 2018;178:545–63.PubMed
30.
Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol. 2007;197:447–56.PubMed
31.
Stewart ZA, Wilinska ME, Hartnell S, O'Neil LK, Rayman G, Scott EM, et al. Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: a randomized controlled crossover trial. Diabetes Care. 2018;41:1391–9.PubMed
32.
Stewart ZA, Wilinska ME, Hartnell S, Temple RC, Rayman G, Stanley KP, et al. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med. 2016;375:644–54.PubMed
33.
Murphy HR. Intensive glycemic treatment during type 1 diabetes pregnancy: a story of (mostly) sweet success! Diabetes Care. 2018;41:1563–71.PubMed
34.
35.
Drincic A, Prahalad P, Greenwood D, Klonoff DC. Evidence-based mobile medical applications in diabetes. Endocrinol Metab Clin N Am. 2016;45:943–65.
36.
Eiland L, McLarney M, Thangavelu T, Drincic A (2018) App-based insulin calculators: current and future state. Curr Diab Rep 18:123–018.
37.
Clements MA, Staggs VS. A mobile app for synchronizing glucometer data: impact on adherence and glycemic control among youths with type 1 diabetes in routine care. J Diabetes Sci Technol. 2017;11:461–7.PubMedPubMedCentral
38.
Sheehy S, Cohen G, Owen KR. Self-management of diabetes in children and young adults using technology and smartphone applications. Curr Diabetes Rev. 2014;10:298–301.PubMed
39.
40.
Quinn CC, Khokhar B, Weed K, Barr E, Gruber-Baldini AL. Older adult self-efficacy study of mobile phone diabetes management. Diabetes Technol Ther. 2015;17:455–61.PubMedPubMedCentral
41.
Arnhold M, Quade M, Kirch W. Mobile applications for diabetics: a systematic review and expert-based usability evaluation considering the special requirements of diabetes patients age 50 years or older. J Med Internet Res. 2014;16:e104.PubMedPubMedCentral
42.
43.
Rodriguez JA, Singh K. The Spanish availability and readability of diabetes apps. J Diabetes Sci Technol. 2018;12:719–24.PubMedPubMedCentral
44.
Williams JP, Schroeder D. Popular glucose tracking apps and use of mHealth by Latinos with diabetes: review. JMIR Mhealth Uhealth. 2015;3:e84.PubMedPubMedCentral
45.
Sarkar U, Gourley GI, Lyles CR, Tieu L, Clarity C, Newmark L, et al. Usability of commercially available mobile applications for diverse patients. J Gen Intern Med. 2016;31:1417–26.PubMedPubMedCentral
46.
Carroll JK, Moorhead A, Bond R, LeBlanc WG, Petrella RJ, Fiscella K. Who uses mobile phone health apps and does use matter? A secondary data analytics approach. J Med Internet Res. 2017;19:e125.PubMedPubMedCentral
47.
Ramchandani N. Virtual coaching to enhance diabetes care. Diabetes Technol Ther. 2019;21:S248–51.PubMed
48.
Greenwood DA, Gee PM, Fatkin KJ, Peeples M. A systematic review of reviews evaluating technology-enabled diabetes self-management education and support. J Diabetes Sci Technol. 2017;11:1015–27.PubMedPubMedCentral
49.
50.
Weinstock RS, Teresi JA, Goland R, Izquierdo R, Palmas W, Eimicke JP, et al. Glycemic control and health disparities in older ethnically diverse underserved adults with diabetes: five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) study. Diabetes Care. 2011;34:274–9.PubMedPubMedCentral
51.
Dy P, Morin PC, Weinstock RS. Use of telemedicine to improve glycemic management in a skilled nursing facility: a pilot study. Telemed J E Health. 2013;19:643–5.PubMed
52.
Trief PM, Izquierdo R, Eimicke JP, Teresi JA, Goland R, Palmas W, et al. Adherence to diabetes self care for white, African-American and Hispanic American telemedicine participants: 5 year results from the IDEATel project. Ethn Health. 2013;18:83–96.PubMed
53.
Zhai YK, Zhu WJ, Cai YL, Sun DX, Zhao J. Clinical- and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis. Medicine (Baltimore). 2014;93:e312.
54.
Lee SWH, Ooi L, Lai YK. Telemedicine for the management of glycemic control and clinical outcomes of type 1 diabetes mellitus: a systematic review and meta-analysis of randomized controlled studies. Front Pharmacol. 2017;8:330.PubMedPubMedCentral
55.
56.
Wood CL, Clements SA, McFann K, Slover R, Thomas JF, Wadwa RP. Use of telemedicine to improve adherence to American Diabetes Association standards in pediatric type 1 diabetes. Diabetes Technol Ther. 2016;18:7–14.PubMed
57.
Sood A, Watts SA, Johnson JK, Hirth S, Aron DC. Telemedicine consultation for patients with diabetes mellitus: a cluster randomised controlled trial. J Telemed Telecare. 2018;24:385–91.PubMed
58.
Hanna KM. A framework for the youth with type 1 diabetes during the emerging adulthood transition. Nurs Outlook. 2012;60:401–10.PubMedPubMedCentral
59.
Klonoff DC. Behavioral theory: the missing ingredient for digital health tools to change behavior and increase adherence. J Diabetes Sci Technol. 2019;13:276–81.PubMedPubMedCentral
Metadata
Title
Has Technology Improved Diabetes Management in Relation to Age, Gender, and Ethnicity?
Authors
Leslie Eiland
Thiyagarajan Thangavelu
Andjela Drincic
Publication date
01-11-2019
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 11/2019
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-019-1231-5

Other articles of this Issue 11/2019

Current Diabetes Reports 11/2019 Go to the issue

Pediatric Type 2 and Monogenic Diabetes (O Pinhas-Hamiel, Section Editor)

Pregnancy and Gestational Diabetes Mellitus (GDM) in North American Indian Adolescents and Young Adults (AYA): Implications for Girls and Stopping GDM

Obesity (KM Gadde, Section Editor)

Benefit-to-Risk Balance of Weight Loss Interventions in Older Adults with Obesity

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Diabetes and Disasters: Recent Studies and Resources for Preparedness

Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editors)

Timing of Insulin with Meals in the Hospital: a Systems Improvement Approach

Immunology, Transplantation, and Regenerative Medicine (L Piemonti and V Sordi, Section Editors)

Pancreas Transplantation from Donors after Circulatory Death: an Irrational Reluctance?

Obesity (KM Gadde, Section Editor)

The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits